Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
21 hedge funds and large institutions have $21.8M invested in Calliditas Therapeutics AB American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
34% more capital invested
Capital invested by funds: $16.3M → $21.8M (+$5.53M)
24% more funds holding
Funds holding: 17 → 21 (+4)
40% less call options, than puts
Call options by funds: $662K | Put options by funds: $1.1M
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$176K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$28.1K |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
+$18.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.1K |
| 5 |
JP Morgan Chase
New York
|
+$7.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$749K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$217K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$77.4K |
| 4 |
Morgan Stanley
New York
|
-$32.3K |
| 5 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$23.5K |
CALT Hedge Fund Activity: Q4 2023 in Review
21 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q4 2023, worth a combined $21.8M — up 34% from $16.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CALT positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $176K. The largest seller was Deutsche Bank, cutting an estimated $749K.
- 21 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q4 2023, up from 17 in Q3 2023.
- Funds reported $21.8M of Calliditas Therapeutics AB American Depositary Shares stock for Q4 2023, up 34% quarter-over-quarter.
- 5 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q4 2023 and 1 closed out, a net change of +4 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q4 2023 was Susquehanna International Group, an estimated $176K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q4 2023 was Deutsche Bank, an estimated $749K sold.
Based on aggregated 13F filings for Q4 2023.